Atea Pharmaceuticals Inc. (AVIR): Price and Financial Metrics

Atea Pharmaceuticals Inc. (AVIR): $7.49

0.24 (+3.31%)

POWR Rating

Component Grades













Add AVIR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where AVIR ranks best; there it ranks ahead of 89.4% of US stocks.
  • AVIR's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • AVIR's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

AVIR Stock Summary

  • For AVIR, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • As for revenue growth, note that AVIR's revenue has grown 622.49% over the past 12 months; that beats the revenue growth of 98.42% of US companies in our set.
  • The volatility of Atea Pharmaceuticals Inc's share price is greater than that of 99.17% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Atea Pharmaceuticals Inc are MRTX, RCUS, FATE, MORF, and NKTR.
  • AVIR's SEC filings can be seen here. And to visit Atea Pharmaceuticals Inc's official web site, go to

AVIR Valuation Summary

  • AVIR's price/sales ratio is 14.1; this is 271.05% higher than that of the median Healthcare stock.
  • AVIR's price/sales ratio has moved NA NA over the prior 44 weeks.
  • AVIR's price/sales ratio has moved NA NA over the prior 44 weeks.

Below are key valuation metrics over time for AVIR.

Stock Date P/S P/B P/E EV/EBIT
AVIR 2021-08-31 14.1 4.1 69.7 38.7
AVIR 2021-08-30 14.4 4.2 71.5 40.2
AVIR 2021-08-27 14.8 4.3 73.5 41.9
AVIR 2021-08-26 13.8 4.0 68.6 37.7
AVIR 2021-08-25 14.4 4.2 71.7 40.3
AVIR 2021-08-24 14.1 4.1 69.9 38.8

AVIR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AVIR has a Quality Grade of C, ranking ahead of 64.7% of graded US stocks.
  • AVIR's asset turnover comes in at 0.261 -- ranking 171st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AVIR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.261 1 -0.219
2020-12-31 0.110 1 0.072

AVIR Price Target

For more insight on analysts targets of AVIR, see our AVIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.00 Average Broker Recommendation 1.3 (Strong Buy)

AVIR Stock Price Chart Interactive Chart >

Price chart for AVIR

AVIR Price/Volume Stats

Current price $7.49 52-week high $46.91
Prev. close $7.25 52-week low $5.31
Day low $7.18 Volume 608,700
Day high $7.53 Avg. volume 934,021
50-day MA $6.53 Dividend yield N/A
200-day MA $14.05 Market Cap 623.60M

Atea Pharmaceuticals Inc. (AVIR) Company Bio

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

AVIR Latest News Stream

Event/Time News Detail
Loading, please wait...

AVIR Latest Social Stream

Loading social stream, please wait...

View Full AVIR Social Stream

Latest AVIR News From Around the Web

Below are the latest news stories about Atea Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVIR as an investment opportunity.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business update. To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least f

Yahoo | February 22, 2022

Atea Pharmaceuticals (AVIR) Receives a Hold from Leerink Partners

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Atea Pharmaceuticals (AVIR – Research Report) today and set a price target of $10.00. The company's shares closed last Tuesday at $6.42, close to its 52-week low of $6.02. According to, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Aligos Therapeutics. Currently, the analyst consensus on Atea Pharmaceuticals is a Hold with an average price target of $9.33.

Brian Anderson on TipRanks | February 16, 2022

8 Biotech Stocks So Cheap That Their Technology Is Effectively Free

The beleaguered sector is showing no real signs of recovery. That could spell an opportunity for some stocks.

Yahoo | February 16, 2022

10 New Stock Picks of Billionaire Rob Citrone

In this article, we discuss 10 new stock stock picks of billionaire Rob Citrone. If you want to skip our detailed analysis of these stocks, go directly to 5 New Stock Picks of Billionaire Rob Citrone. Rob Citrone is an American hedge fund manager who in 1999 co-founded Discovery Capital Management, a hedge fund that […]

Yahoo | February 14, 2022

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Yahoo | February 11, 2022

Read More 'AVIR' Stories Here

AVIR Price Returns

1-mo 27.16%
3-mo 26.73%
6-mo -2.47%
1-year -66.61%
3-year N/A
5-year N/A
YTD -16.22%
2021 -78.60%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8242 seconds.